Wells Fargo Believes Agilent (A) Still Has Room to Grow


Wells Fargo analyst Dan Leonard maintained a Buy rating on Agilent (A) yesterday. The company’s shares closed last Monday at $112.21, close to its 52-week high of $117.50.

According to TipRanks.com, Leonard is a 4-star analyst with an average return of 10.3% and a 66.7% success rate. Leonard covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Quest Diagnostics, and Mettler-Toledo.

Currently, the analyst consensus on Agilent is a Strong Buy with an average price target of $130.00, which is a 16.7% upside from current levels. In a report issued on November 17, Cleveland Research also upgraded the stock to Buy.

See today’s analyst top recommended stocks >>

Agilent’s market cap is currently $34.19B and has a P/E ratio of 50.00. The company has a Price to Book ratio of 68.51.

Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of A in relation to earlier this year. Last month, Michael R. McMullen, the CEO & President of A sold 24,636 shares for a total of $2,094,060.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment comprises activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts